Caricamento...
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint block...
Salvato in:
| Pubblicato in: | J Exp Clin Cancer Res |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6380009/ https://ncbi.nlm.nih.gov/pubmed/30777100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1085-3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|